Gould Asset Management LLC CA Has $373,000 Position in Bristol-Myers Squibb (NYSE:BMY)

Gould Asset Management LLC CA lessened its holdings in Bristol-Myers Squibb (NYSE:BMY) by 23.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 7,270 shares of the biopharmaceutical company’s stock after selling 2,250 shares during the period. Gould Asset Management LLC CA’s holdings in Bristol-Myers Squibb were worth $373,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. Van Cleef Asset Management Inc raised its holdings in Bristol-Myers Squibb by 23.1% in the 4th quarter. Van Cleef Asset Management Inc now owns 17,576 shares of the biopharmaceutical company’s stock valued at $902,000 after buying an additional 3,299 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich raised its holdings in Bristol-Myers Squibb by 91.7% during the 4th quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,207,453 shares of the biopharmaceutical company’s stock worth $61,954,000 after purchasing an additional 577,428 shares during the last quarter. Syon Capital LLC raised its holdings in Bristol-Myers Squibb by 95.9% during the 4th quarter. Syon Capital LLC now owns 13,425 shares of the biopharmaceutical company’s stock worth $689,000 after purchasing an additional 6,573 shares during the last quarter. Eley Financial Management Inc raised its holdings in Bristol-Myers Squibb by 1.5% during the 4th quarter. Eley Financial Management Inc now owns 37,431 shares of the biopharmaceutical company’s stock worth $1,921,000 after purchasing an additional 554 shares during the last quarter. Finally, Disciplined Equity Management Inc. bought a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $132,000. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Up 0.4 %

Bristol-Myers Squibb stock traded up $0.16 during trading hours on Friday, hitting $44.86. 21,279,666 shares of the stock traded hands, compared to its average volume of 15,968,238. The firm’s 50-day moving average price is $51.13 and its two-hundred day moving average price is $51.26. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24. The company has a market cap of $90.92 billion, a PE ratio of 11.70, a PEG ratio of 1.47 and a beta of 0.39. Bristol-Myers Squibb has a one year low of $44.34 and a one year high of $69.10.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The firm had revenue of $11.87 billion during the quarter, compared to analyst estimates of $11.45 billion. During the same period last year, the business earned $2.05 earnings per share. The business’s revenue was up 4.7% on a year-over-year basis. On average, research analysts forecast that Bristol-Myers Squibb will post 6.63 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be paid a dividend of $0.60 per share. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a yield of 5.35%. Bristol-Myers Squibb’s dividend payout ratio is presently 62.18%.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Bank of America lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $68.00 to $60.00 in a research note on Wednesday, January 3rd. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Monday, April 15th. Redburn Atlantic lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $77.00 to $54.00 in a report on Tuesday, February 6th. Finally, Societe Generale lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $60.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.